article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.

DEA 111
article thumbnail

DEA finally ends fed monopoly on schwaggy research-grade cannabis

SpeedWeed

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.

DEA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. BRC) told The Cannigma this week.

DEA 133
article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA

DEA 52
article thumbnail

The DEA Is Finally About to End the Federal Monopoly on Research Cannabis Cultivators

SpeedWeed

After years of delays, legal challenges, and obfuscation, the US Drug Enforcement Agency (DEA) finally announced that it would begin evaluating applications for federally-licensed research cannabis cultivators. . In 2019, a federal judge forced the DEA to explain its inaction.

DEA 52
article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66
article thumbnail

Press Release: Cybin Granted DEA Schedule I Manufacturing License

Cannabis Law Report

Cybin Granted DEA Schedule I Manufacturing License. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company’s research lab in the Boston area.

DEA 52